The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer

T-cell recruiting chemokines are required for a successful immune intervention in ovarian cancer, and also for the efficacy of modern anticancer agents such as PARP inhibitors. The chemokine CX3CL1 recruits tumour-suppressive T-cells into solid tumours, but also mediates cell–cell adhesions, e.g. of...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefanie Seitz, Tobias F. Dreyer, Christoph Stange, Katja Steiger, Dirk Wohlleber, Martina Anton, Thuý An Pham, Dominique Sauter-Peschke, Ute Reuning, Gabriele Multhoff, Wilko Weichert, Marion Kiechle, Viktor Magdolen, Holger Bronger
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558625000090
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832557572182245376
author Stefanie Seitz
Tobias F. Dreyer
Christoph Stange
Katja Steiger
Dirk Wohlleber
Martina Anton
Thuý An Pham
Dominique Sauter-Peschke
Ute Reuning
Gabriele Multhoff
Wilko Weichert
Marion Kiechle
Viktor Magdolen
Holger Bronger
author_facet Stefanie Seitz
Tobias F. Dreyer
Christoph Stange
Katja Steiger
Dirk Wohlleber
Martina Anton
Thuý An Pham
Dominique Sauter-Peschke
Ute Reuning
Gabriele Multhoff
Wilko Weichert
Marion Kiechle
Viktor Magdolen
Holger Bronger
author_sort Stefanie Seitz
collection DOAJ
description T-cell recruiting chemokines are required for a successful immune intervention in ovarian cancer, and also for the efficacy of modern anticancer agents such as PARP inhibitors. The chemokine CX3CL1 recruits tumour-suppressive T-cells into solid tumours, but also mediates cell–cell adhesions, e.g. of tumour cells, through its membrane-bound form. So far, its role in ovarian cancer has only been rudimentarily addressed. We show that high CX3CL1 expression significantly correlates with worsened survival in human high-grade serous ovarian cancer (n=219). In preclinical ovarian cancer, CX3CL1 plays a dual role, as it enhances the adaptive anti-tumour response, but overall still promotes tumour growth, the latter as a feature of the intraperitoneal environment. Moreover, PARP inhibitors are able to increase CX3CL1 release from human ovarian cancer cells. Collectively, our study shows that CX3CL1 is a driver of intraperitoneal tumour growth in ovarian cancer, a feature that may compromise the anticancer effect of CX3CL1-inducing PARP inhibitors.
format Article
id doaj-art-39f4087d4caa4b088d4e9c5baea8653b
institution Kabale University
issn 1476-5586
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Neoplasia: An International Journal for Oncology Research
spelling doaj-art-39f4087d4caa4b088d4e9c5baea8653b2025-02-03T04:16:37ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55862025-02-0160101130The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancerStefanie Seitz0Tobias F. Dreyer1Christoph Stange2Katja Steiger3Dirk Wohlleber4Martina Anton5Thuý An Pham6Dominique Sauter-Peschke7Ute Reuning8Gabriele Multhoff9Wilko Weichert10Marion Kiechle11Viktor Magdolen12Holger Bronger13Department of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, GermanyDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, GermanyDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, GermanyComparative Experimental Pathology, Institute of Pathology, Technical University of Munich, 81675 Munich, Germany; Institute of Pathology, Technical University of Munich, 81675 Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, GermanyInstitute of Molecular Immunology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, GermanyInstitute of Molecular Immunology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, GermanyDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, GermanyDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, GermanyDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, GermanyDepartment of Radiation Oncology, Technical University of Munich, TranslaTUM, 81675 Munich, GermanyInstitute of Pathology, Technical University of Munich, 81675 Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, GermanyDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, GermanyDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Corresponding author at: Department of Gynecology and Obstetrics, Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany.T-cell recruiting chemokines are required for a successful immune intervention in ovarian cancer, and also for the efficacy of modern anticancer agents such as PARP inhibitors. The chemokine CX3CL1 recruits tumour-suppressive T-cells into solid tumours, but also mediates cell–cell adhesions, e.g. of tumour cells, through its membrane-bound form. So far, its role in ovarian cancer has only been rudimentarily addressed. We show that high CX3CL1 expression significantly correlates with worsened survival in human high-grade serous ovarian cancer (n=219). In preclinical ovarian cancer, CX3CL1 plays a dual role, as it enhances the adaptive anti-tumour response, but overall still promotes tumour growth, the latter as a feature of the intraperitoneal environment. Moreover, PARP inhibitors are able to increase CX3CL1 release from human ovarian cancer cells. Collectively, our study shows that CX3CL1 is a driver of intraperitoneal tumour growth in ovarian cancer, a feature that may compromise the anticancer effect of CX3CL1-inducing PARP inhibitors.http://www.sciencedirect.com/science/article/pii/S1476558625000090ChemokinesCX3CL1Tumour-infiltrating lymphocytesPARP inhibitionMouse model
spellingShingle Stefanie Seitz
Tobias F. Dreyer
Christoph Stange
Katja Steiger
Dirk Wohlleber
Martina Anton
Thuý An Pham
Dominique Sauter-Peschke
Ute Reuning
Gabriele Multhoff
Wilko Weichert
Marion Kiechle
Viktor Magdolen
Holger Bronger
The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
Neoplasia: An International Journal for Oncology Research
Chemokines
CX3CL1
Tumour-infiltrating lymphocytes
PARP inhibition
Mouse model
title The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
title_full The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
title_fullStr The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
title_full_unstemmed The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
title_short The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
title_sort chemokine cx3cl1 promotes intraperitoneal tumour growth despite enhanced t cell recruitment in ovarian cancer
topic Chemokines
CX3CL1
Tumour-infiltrating lymphocytes
PARP inhibition
Mouse model
url http://www.sciencedirect.com/science/article/pii/S1476558625000090
work_keys_str_mv AT stefanieseitz thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT tobiasfdreyer thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT christophstange thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT katjasteiger thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT dirkwohlleber thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT martinaanton thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT thuyanpham thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT dominiquesauterpeschke thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT utereuning thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT gabrielemulthoff thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT wilkoweichert thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT marionkiechle thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT viktormagdolen thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT holgerbronger thechemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT stefanieseitz chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT tobiasfdreyer chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT christophstange chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT katjasteiger chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT dirkwohlleber chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT martinaanton chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT thuyanpham chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT dominiquesauterpeschke chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT utereuning chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT gabrielemulthoff chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT wilkoweichert chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT marionkiechle chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT viktormagdolen chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer
AT holgerbronger chemokinecx3cl1promotesintraperitonealtumourgrowthdespiteenhancedtcellrecruitmentinovariancancer